Overview

Study of Erlotinib in Patients With Non-Metastatic Prostate Cancer With a Rising Prostate Specific Antigen (PSA) on Hormone Therapy

Status:
Completed

Trial end date:
2008-08-01

Target enrollment:

Participant gender:

Summary

The primary objective of this study is to evaluate the effect of erlotinib on the PSA response rate in patients with non-metastatic prostate cancer and a rising PSA on androgen deprivation therapy. The secondary objectives are to evaluate the effect of erlotinib on the duration of PSA response, to evaluate the effect on the time to PSA progression, to evaluate the toxicity of erlotinib in this patient population, and lastly, to correlate the effect of erlotinib with various epidermal growth factor receptor (EGFR)-related proteins using baseline immunohistochemical (IHC) studies on tissue blocks and peripheral blood mononuclear cells.

Phase:

Phase 2

Details

Lead Sponsor:

NorthShore University HealthSystem
NorthShore University HealthSystem Research Institute

Collaborators:

Genentech, Inc.
Northwestern University

Treatments:

Erlotinib Hydrochloride
Hormones